Title: PTEN INHIBITOR OR MAXI-K CHANNELS OPENER

Abstract: A new PTEN opener or a new opener of a large conductance Ca^{2+}-activated K^{+} channel (Maxi-K channel) which comprises as an active ingredient a tetracyloalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, which is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further for inhibiting of Gram negative sepis and cell migration and cell invasion due to inhibition of PTEN and is further useful as a medicament for the treatment of neuronal disorders, for example, an anticonvulsant, a neuroprotecting agent, a medicament for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson’s disease, epilepsy, migraine, and Alzheimer’s disease, etc.

Diagram: Y-Maze

Graphs: 1) Acute Entries, 2) Alternations
Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
DESCRIPTION

PTEN INHIBITOR OR MAXI-K CHANNELS OPENER

5 TECHNICAL FIELD

The present invention relates to a new PTEN inhibitor or a new Maxi-K channels opener. More particularly, it relates to a PTEN inhibitor or new Maxi-K channels opener, which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I):

![Chemical structure]

wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus means a single bond or a double bond, or a salt thereof.

TECHNICAL BACKGROUND

PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) was isolated as a tumor suppressor gene in 1997, and since then the physiological functions thereof have been analyzed from various viewpoints. It is reported
in 1998 that the PTEN gene product exhibits a new phosphatase activity, i.e. it is able to dephosphorylate a phosphatidylinositol 3,4,5-trisphosphate (PIP3) substrate, which is a lipid second messenger, at D3 position thereof (cf. Beitner-Johnson D, Millhorn DE, J. Biol. Chem., 273: pp. 13375-13378, 1998).

In view of the functions of PTEN, it is expected that when inhibition of PTEN will be effective for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further effective for inhibiting of Gram negative sepsis and cell migration and cell invasion.

Besides, it is known that the opening of potassium channel induces flowing the intracellular potassium ion out of cells which results in negative intracellular potential and that the potassium channel is voltage-dependent and is controlled intracellular calcium concentration and intracellular ATP. Maxi-K channel is a class of large conductance calcium sensitive potassium channels, and the activity of Maxi-K channels is controlled by intracellular calcium concentration and membrane potential, etc. The Maxi-K channels are widely distributed within the living body such as neurons, heart cells, smooth muscle cells, and the opening of the Maxi-K channels induces hyperpolarization of cells. It is also known that the opening of the Maxi-K channels is useful for the treatment
of neuronal disorders, for example, as a medicament such as (1) an anticonvulsant, (2) a medicine for neuroprotection, for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson's disease, epilepsy, migraine, and Alzheimer's disease, (3) a medicine for control of a pain, (4) a medicine for treating urge urinary incontinence, intestinal hypermotility, uterine contractility, anxiety, and depression.

DISCLOSURE OF THE INVENTION

During the studies on PTEN, the present inventor has found that the tetrazolylalkoxy-dihydrocarbostyril compounds of the formula (I) or a salt thereof as mentioned above, particularly 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-carbostyril or a salt thereof, which are known to have platelet aggregation inhibitory activity and vasodilating activity, exhibit an activity of inhibiting PTEN and hence are useful as a PTEN inhibitor, and then the present invention has been accomplished.

Further, during the studies on functional analysis of Maxi-K channels, the present inventor has found that the tetrazolylalkoxy-dihydrocarbostyril compounds of the formula (I) or a salt thereof as mentioned above, particularly 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]
3,4-dihydrocarbostyril or a salt thereof, which are known to have platelet aggregation inhibitory activity and vasodilating activity, exhibit an activity of opening of Maxi-K channels and hence are useful as a Maxi-K channels opener, and then the present invention has been accomplished.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a suppression of the TNF-α (50 ng/ml)-stimulated increased PTEN phosphorylation level by cilostazol (tradename of 6-{4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy}-3,4-dihydro-carbostyril).

Fig. 2 shows effects of drugs on opening of calcium-activated K⁺ current in SK-N-SH cells, and Fig. 2A shows the effects of cilostazol (tradename of 6-{4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy}-3,4-dihydrocarbostyril), Fig. 2B shows effects of cilostazol and/or glibenclamide (abbreviated as "GBC", which is commercially available antidiabetics, suggestive of absence of opening of ATP-sensitive K⁺ channels), and Fig. 2C shows effects of cilostazol and/or iberiotoxin (abbreviated as "Ibtx", which is known as Maxi-K⁺ channel blocker, suggestive of opening of Maxi-K⁺ channels).

Fig. 3 shows total amyloid-beta concentration (A-Beta 40 and A-Beta 42 levels) in brains of mice in the control
and cilostazole treated groups which were detected by ELISA.

Fig. 4 shows a summary of experimental results obtained from the Y-maze behavior paradigm for testing the effects on Alzheimer's disease of the compound of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a new PTEN inhibitor or new Maxi-K channels opener which comprises as an active ingredient a tetrazolylalkoxy-carbostyril compound of the formula (I) or a salt thereof. The present invention further provides a method for inhibiting PTEN and a method for opening Maxi-K channels, which comprises administering the tetrazolylalkoxy-carbostyril compound (I) or a salt thereof to a patient in need of such treatments, and further provides a use of the tetrazolylalkoxy-carbostyril compound (I) or a salt thereof for inhibiting PTEN as well as for opening Maxi-K channels.

The compound of the formula (I) or a salt thereof has excellent PTEN inhibitory effect and hence the PTEN inhibitor of the present invention comprising as an active ingredient the compound of the formula (I) or a salt thereof is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further for inhibiting of Gram negative sepsis
and cell migration and cell invasion without any side effect due to inhibition of PTEN.

Furthermore, the compound of the formula (I) or a salt thereof has excellent effect of opening of a large conductance calcium-activated K⁺ channel (Maxi-K channels) and hence the Maxi-K channel opener of the present invention comprising as an active ingredient the compound of the formula (I) or a salt thereof is useful as a medicament for the treatment of neuronal disorders, for example, an anticonvulsant, a neuroprotecting agent, a medicament for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson's disease, epilepsy, migraine, and Alzheimer's disease, pain, urge urinary incontinence, intestinal hypermotility, uterine contractility, anxiety, and depression.

The tetrazolylalkoxy-dihydrocarbostyril compounds of the formula (I) and processes for preparation thereof are disclosed in JP-63-20235.

In the formula (I), the "cycloalkyl group" includes C₁₋₄ cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. but preferable one is cyclohexyl. The "lower alkylene group" includes C₁₋₄ alkylene groups such as methylene, ethylene, propylene, butylene, etc. but preferable one is butylene.
Particularly preferred compound is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-carbostyril, which has been sold as a vasodilator under a tradename of cilostazol.

The compound of the formula (I) of the present invention can be used in bulk or preferably in the form of a pharmaceutical preparation with a conventional pharmaceutical carrier or diluent. The dosage form is not limited to a specific form, but may be in any conventional dosage forms, for example, preparations for oral administration, such as tablets, capsules, granules, various liquid preparations suitable for oral administration, or preparations for parenteral administration, such as injections, suppositories. The dosage is not limited to a specific range but is usually in the range of 100 to 400 mg per day in adult (50kg of body weight) which is administered once or being divided in one to several times. The active compound is preferably contained in the preparation in an amount of 50 to 100 mg per dosage unit.

The preparation for injection is usually prepared in the form of a liquid preparation, an emulsion, or a suspension, which are sterilized and further are preferably made isotonic to the blood. The preparations in the form of a liquid, emulsion or suspension are usually prepared by using conventional pharmaceutical diluents, for example,
water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters. These preparations may be incorporated with an isotonic agent such as sodium chloride, glucose, glycerin in an amount sufficient for making isotonic and may further incorporated with conventional solubilizers, buffers, anesthetizing agents, and optionally colorants, preservatives, fragrant materials, flavors, sweetening agents, and other medicaments.

The preparations such as tablets, capsules, liquid for oral administration may be prepared by a conventional method. The tablets may be prepared by mixing with conventional pharmaceutical carriers such as gelatin, starches, lactose, magnesium stearate, talc, gum arabic, and the like. The capsules may be prepared by mixing with inert pharmaceutical fillers or diluents and filled in a hard gelatin capsule or a soft capsule. The oral liquid preparations such as syrups or elixirs are prepared by mixing the active compound and sweetening agents (e.g. sucrose), preservatives (e.g. methylparaben, propylparaben), colorants, flavors, and the like. The preparations for parenteral administration may also be prepared by a conventional method, for example, by dissolving the compound (I) of the present invention in a sterilized
aqueous carrier, preferably water or a saline solution. Preferred liquid preparation suitable for parenteral administration is prepared by dissolving about 50 - 100 mg of the active compound (I) in water and an organic solvent and further in a polyethylene glycol having a molecular weight of 300 to 5000, which is preferably incorporated with a lubricant such as sodium carboxy-methylcellulose, methyl-cellulose, polyvinylpyrrolidone, and polyvinyl alcohol. The above liquid preparations may preferably be further incorporated with a disinfectant (e.g. benzyl alcohol, phenol, thimerosal), a fungicide, and further optionally with an isotonic agent (e.g. sucrose, sodium chloride), a topical anesthetic, a stabilizer, a buffer, and the like. In view of keeping stability, the preparation for parenteral administration may be filled in a capsule, followed by removing the aqueous medium by a conventional lyophilizing technique, and is recovered into a liquid preparation by dissolving in an aqueous medium when used.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is illustrated by the following preparation examples and experiments of suppressing effects of the compounds on the increase of PTEN phosphorylation which is stimulated by TNF-α or on the Maxi-K⁺ channel
opening, but should not be construed to be limited thereto.

**Preparation 1**

Preparation of injection preparation:

<table>
<thead>
<tr>
<th>Components</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 6-[4-[(1-Cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril</td>
<td>5 g</td>
</tr>
<tr>
<td>Polyethyleneglycol (molecular weight: 4000)</td>
<td>0.3 g</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>0.9 g</td>
</tr>
<tr>
<td>Polyoxyethylene sorbitan monooleate</td>
<td>0.4 g</td>
</tr>
<tr>
<td>10 Sodium metabisulfite</td>
<td>0.1 g</td>
</tr>
<tr>
<td>Methylparaben</td>
<td>0.18 g</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>0.02 g</td>
</tr>
<tr>
<td>Distilled water for injection</td>
<td>10.0 ml</td>
</tr>
</tbody>
</table>

The above parabens, sodium metabisulfite and sodium chloride are dissolved in a half amount of the above distilled water with stirring at 80°C. The mixture is cooled to 40°C, and thereto are dissolved the active compound, and further polyethylene glycol and polyoxyethylene sorbitan monooleate. The remaining distilled water for injection is added to the mixture, sterilized by filtering with a filter paper to give the desired injection preparation.

**Preparation 2**

Preparation of tablets:

<table>
<thead>
<tr>
<th>Components</th>
<th>Amount</th>
</tr>
</thead>
</table>
6-[4-(1-Cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril 100 g
Lactose (Japanese Pharmacopeia) 40 g
Cornstarch (Japanese Pharmacopeia) 40 g
Crystalline cellulose (Japanese Pharmacopeia) 20 g
Hydroxypropylcellulose (Japanese Pharmacopeia) 4 g
Magnesium stearate (Japanese Pharmacopeia) 2 g

The above compound of the present invention, lactose, cornstarch and crystalline cellulose are mixed well and the mixture is granulated with 5% aqueous solution of hydroxypropylcellulose, and the granulated mixture is sieved with 200 mesh screen to dry the granules carefully, and then the granules are tabletted by a conventional method to give tablets (1000 tablets).

15 Pharmacological Experiments

The effects for suppression of the TNF-α-stimulated increased PTEN phosphorylation level by the representative compound of the present invention: cilostazol were tested

Further, the effects on opening of Maxi-K channels of the representative compound of the present invention: cilostazol and some commercially available Maxi-K channels opener or blocker were tested.

Experiment 1

Effects of cilostazol on the suppression of the TNF-α-stimulated increase in PTEN phosphorylation level:
Materials:

Cell cultures: SK-N-SH (KCLB 30011, human brain neuroblastoma) cells were cultured in Eagle's minimum essential medium (MEM) with 2 mM L-glutamine and 1.0 mM sodium pyruvate supplemented with 10% heat-inactivated fetal bovine serum. Cells were grown to confluence at 37°C in 5% CO₂ and used for experiments at no greater than passage 20.

Preparation of TNF-α solution: TNF-α (Upstate Biotechnology, Inc., Lake Placid, NY) was dissolved in the phosphate buffered saline as a 10 µg/ml stock solution.

Method:

Western blot analysis: The confluent cells received MEM medium with 1% FBS plus cilostazol 3 hours prior to stimulation with TNF-α and then were exposed to TNF-α for one hour.

The cells were lysed in lysis buffer containing 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.02% sodium azide, 100 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin and 1% Triton X-100. Following centrifugation at 12,000 rpm, 50 µg of total protein was loaded into 8 or 10% SDS-PAGE gel, and transferred to nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway, NJ). The blocked membranes were then incubated with the indicated antibody, and the immunoreactive bands were visualized using chemiluminescent
reagent as recommended by Supersignal West Dura Extended Duration Substrate Kit (Pierce, Rockford, IL). The signals of the bands were quantified using a GS-710 Calibrated imaging Densitometer (Bio-Rad Laboratories, Hercules, CA). The results were expressed as a relative density. Polyclonal antibodies against PTEN, phospho-PTEN (Ser 380/Thr382/383) were from the Cell Signaling Technology (Beverly, MA).

Statistical analysis: The results are expressed as means ± SEM. Statistical differences between groups were determined by Student's t-test. p<0.05 was considered to be significant.

Results:

The Western blot and densitometric analysis are shown in the accompanying Fig. 1.

As is seen from Fig. 1, cilostazol (1, 10 and 100 μM) concentration-dependently suppressed the TNF-α (50 ng/ml)-stimulated increased PTEN phosphorylation level.

From the above experimental results, it is clear that cilostazol showed potent activity of inhibiting PTEN phosphorylation.

Experiment 2

Materials:

Cell cultures: SK-N-SH (KCLB 30011, human brain neuroblastoma) cells were cultured in Eagle's minimum
essential medium (MEM) with 2 mM L-glutamine and 1.0 mM sodium pyruvate supplemented with 10% heat-inactivated fetal bovine serum. Cells were grown to confluence at 37°C in 5% CO₂ and used for experiments at no greater than passage 20.

Test drugs:

(1) Cilostazol (a compound of the present invention, a tradename of 6-[(4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-carbostyril).

(2) Glibenclamide (abbreviated as "GBC", general name: Glyburide, chemical name: 5-chloro-N-[2-[4-[[[(cyclohexyl-amino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-benzamide, which is commercially available antidiabetics, a blocker of ATP-sensitive K⁺ channels).

(3) Iberiotoxin (abbreviated as "Ibtx", which is known as Maxi-K⁺ channel blocker).

Method:

Recording of the whole-cell K⁺ current: The experiments were performed in a small bath (0.5 ml) mounted on the stage of an inverted microscope (Nikon model TE300, Tokyo, Japan) perfused continuously at a flow rate of 1 ml/min. Using the whole-cell configuration of the patch clamp technique, the K⁺ currents were recorded at room temperature (20~22°C) with an Axopatch-200B patch clamp amplifier (Axon Instruments, Foster City, CA). Currents
were sampled at 1 to 10 kHz after anti-alias filtering at 0.5 to 5 kHz. Data acquisition and command potentials were controlled by pClamp 6.0.3 software (Axon Instruments, Foster City, CA). To ensure the voltage clamp quality, electrode resistance was kept below 3 MΩ. Junction potentials were zeroed with the electrode in the standard bath solution. Gigaohm seal formation was achieved by suction and, after establishing the whole cell configuration, the capacitive transients elicited by symmetrical 10 mV voltage clamp steps from -80 mV were recorded at 50 kHz for calculation of cell capacitance. The normal bath solution for the whole-cell recordings was: NaCl 130 mM, KCl 5 mM, MgCl₂ 1.2 mM, CaCl₂ 1.8 mM, HEPES 10 mM, glucose 5.2 mM and the pH was adjusted to 7.4 with NaOH. Pipettes were filled with KCl 140 mM, MgCl₂ 0.5 mM, CaCl₂ 0.1 mM, ethylenebis(oxonitrilo) tetra-acetic acid (EGTA) 0.09 mM, HEPES 10 mM, glucose 10 mM and the pH was adjusted to 7.4 with KOH.

After establishment of whole-cell recordings and collecting control recordings for approximately 5 minutes until the current elicited by depolarization stabilized, cilostazol was applied to the bath. In the experiments, using glibenclamide or iberiotoxin, cilostazol was applied to the bath about 20 minutes after administering glibenclamide or iberiotoxin.
Results:

The test results are shown in the accompanying Fig. 2, wherein Fig. 2A shows the effects of cilostazol, Fig. 2B shows effects of cilostazol and/or glibenclamide ("GBC", suggestive of opening of Maxi-K^+ channels), and Fig. 2C shows effects of cilostazol and/or iberiotoxin ("Ibtx", Maxi-K^+ channel blocker).

As is seen from Fig. 2, the current was significantly increased by cilostazol, but on the other hand, it reversibly blocked by addition of iberiotoxin (100 nM) to the bath, but not by glibenclamide (10 μM). The increase in Maxi-K channel-mediated currents was given by cilostazol even in co-existence of glibenclamide, while glibenclamide alone could not increase the Maxi-K channel-mediated currents. When cilostazol was added to the cells together with iberiotoxin, Maxi-K channel blocker, increase of the current was rather less than iberiotoxin alone.

**Experiment 3**

1. **Compound Preparation**

   Vehicle control; 0.5% carboxymethylcellulose. twice daily (n=10)

   Cilostazol; 100 mg/kg,. twice daily (n=10)

   Triturate a small amount of powder (cilostazol) by agate mortar. Add two or three drops of 0.5% carboxy-methylcellulose (CMC) and triturate well. Add 4-5ml of
0.5% CMC and recover the suspended cilostazol to a light protected glass bottle.

Test compound preparation weekly at the concentration of 1000 mg/50ml, and store protected from light at 4°C.

5 Compound Administration

Before administration, sonicate the stock bottle of test compound by ultra-sonic sonicator and mix well.

Compounds via twice daily oral gavage as per group assignments.

10 Vehicle Control (0.5% carboxymethylcellulose:CMC; 1 kg/5ml) twice daily gavage. Test Compound (Cilostazol; 100 mg/kg/5ml) twice daily gavage.

2. Methods of observations, examinations and measurements

   a. The animals (8 weeks of age, Hemizygous transgenic mice that express mutant human APP\textsubscript{K670N,M671L}/line Tg2576) were randomized into 2 groups of double transgenic APP/PS1 mice (control and cilostazol, total = 20 mice). Each mouse was administered twice daily by gavage for 6 weeks, as shown in the following table:

<table>
<thead>
<tr>
<th>Protocol Design</th>
<th>Start Age</th>
<th>Number of Mice</th>
<th>Age at End</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (Vehicle)</td>
<td>8 weeks</td>
<td>10</td>
<td>14 weeks</td>
</tr>
<tr>
<td>Test Compound</td>
<td>8 weeks</td>
<td>10</td>
<td>14 weeks</td>
</tr>
<tr>
<td>Total Mice = 20</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

   b. Mice were genotyped at the beginning and end of the study.
c. Mice were subjected to the Y-maze behavior paradigm prior to completing the in-life phase.

d. The mice were sacrificed at 14 weeks of age.

e. Upon sacrifice, 1 ml of blood was collected for cilostazol blood concentration measurement, and APP/PS1 mice were perfused with saline. Brains were hemisected with one hemisphere fixed and the other hemisphere frozen.

f. The frozen hemisphere was homogenized and analyzed for total amyloid-beta concentration via ELISA.

Total A-Beta 40 and total A-Beta 42 levels in brains of mice were detected in the control group and in cilostazol treated group. The results are shown in the accompanying Fig. 3.

3. Procedure

The following procedure outlines the steps taken to perform the test "Spontaneous Alternation in the Y-maze". Mice have an innate tendency to explore their environment. Successful exploration depends on the ability to avoid places recently visited, where food may have been depleted or absent ("spontaneous alternation"). The Y-maze is an ethologically based test that does not involve reward delivery. Mice with compromised "working memory" function cannot hold information regarding places just visited in their working memory; therefore they show decreased spontaneous alternation.
Published results have shown decreased spontaneous alternation and increased exploration in certain transgenic mouse strains, for example APP/PS1 mice. Cilostazol has an anti-platelet and vaso-dilating action, which has an indication for ASO and prevention of secondary brain infarction.

These actions of Cilostazol may contribute to reduce the deposition of amyloid-beta protein, and improve a behavior of Alzheimer's dementia.

i. Bring mice to be tested into the testing room. Avoid bringing many mice (more than three cages) into the testing area at once, as this may influence their behavior. (Optional, do only if animals are not marked otherwise, e.g. by transponders or clearly visible tattoo.) Mark their tails with a non-toxic color marker in the following order:

1: red
2: green
3: blue
4: black

ii. Experiments may be recorded by video. This produces a permanent record and allows the investigators to revisit the experiments if there are any questions.

iii. Take the first mouse to be tested out of its home cage by the base of the tail, and weigh it. Record the weight in the Y-Maze Data Spreadsheet. Place the mice back
in the cage. (Alternatively, mice may be weighed before the start of the experiment, e.g. on the previous day)

iv. Leave the mice undisturbed for 1 hour before the testing starts so that they can acclimatize to the room. Extra care should be taken to ensure that cages are not left adjacent to one particular arm, as the smell, for example, may influence the entry of a mouse into a single arm. Therefore, either place the cage at a distance from the apparatus or ensure that the cages are evenly distributed around the room. (e.g. may introduce three cages at once ? one in proximity to each arm). Technician may be present in the testing room, but must not disturb the mice.

v. Before the test starts, wipe the inside of the Y-maze with isopropanol.

vi. Handle mice gently, holding by tail and let rest on arm, taking care not to let mouse plunge down head first into maze. Mice are individually placed in the center of a Y maze, with all three arms (arm A, arm B and arm C) available for exploration, for a period of 8 minutes.

vii. Record all entries on a printout of the Y-maze data sheet. Enter an “A” into the ARM ENTERED field if the mouse completely enters arm A, etc.

In the same row, enter “end” into OBSERVATIONS if the mouse explores the arm to the end, “R” for each time the mouse rears (sits on its hind legs with forelegs free) or “L” if
it leans ("explores up the wall" with the forefeet touching the wall), and "F" if it freezes (remains motionless for 5 seconds or more). If the mouse goes back and forth within arm A, enter another "bf" in OBSERVATIONS in the same row.

Enter any other observations in full text. If there is not enough time to enter observations, skip them. If the mouse returns to the center, start a new line. Enter "A" in the new line if mouse returns to arm A, "B" for arm B or "C" for arm C.

viii. After 8 minutes, remove the mice by the tail and place them in their home cage. Record the number of boli and whether or not the mice urinated in the Y-maze spreadsheet. Wipe the inside of the Y-maze with isopropanol. Use brush to get in corners, clean both walls and floor. Make sure that the Y-maze is clean and clear of any smell, bedding or food that may have been brought into the maze by a previous mouse. Make sure the Y-maze is dry after cleaning with alcohol. Make sure no cleaning material (such as tissue) is left behind in the maze.

ix. Repeat steps for all of the mice to be tested.

x. After the test, transfer data from hard copy to Excel spreadsheet.

The results obtained from the Y-maze behavior paradigm are summarized in the accompanying Fig. 4.

xi. Data analysis: An alternation is defined as a
visit to all three arms without re-entry (ABC, ACB, BAC, BCA, CAB or CBA). Analyze each ARM ENTRY separately and determine whether it completed an alternation. The sequence ABCABC has four alternations, the first ends with C, the next with A, then B, then C. The sequence ABCBAC has only three alternations, the first ending in C, the second ending with A, and the third with C. % alternations is (number of observed alternations)/(number of possible alternations). If n arms are visited, the highest possible number of alternations is n-2. If the animal moves randomly, 22% alternations would be expected (3*2*1/3*3*3). Global activity is reflected in the total number of visits to the different arms. ACTIVITY is therefore (total number of arm entries)/minutes of observation).

Thus, the tetrazolylalkoxy-dihydrocarbostyril compounds (I) or a salt thereof of the present invention is effective for opening Maxi-K Channels and is useful for the treatment of neuronal disorders, particularly for the treatment of Alzheimer's disease.

INDUSTRIAL APPLICABILITY

The present invention provides a composition comprising as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound (I) or a salt thereof, which has excellent PEN inhibitory effects and is useful as a
medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further for inhibiting of Gram negative sepsis and cell migration and cell invasion without any side effect due to inhibition of PTEN. The composition of the present invention is further useful as an opener of a large conductance Ca^{2+}-activated K' channel (Maxi-K channel) and hence as a medicament for the treatment of neuronal disorders, for example, an anti-convulsant, a neuroprotecting agent, a medicament for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson's disease, epilepsy, migraine, and Alzheimer's disease, etc.
CLAIMS

1. A PTEN inhibitor which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I):

   ![](formula_image)

   wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus means a single bond or a double bond, or a salt thereof.

2. The PTEN inhibitor according to claim 1, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

3. A pharmaceutical composition for inhibition of PTEN which comprises as an active ingredient tetrazolylalkoxy-dihydrocarbostyril compound (I) or a salt thereof as set forth in claim 1 in admixture with a conventional pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition according to claim 3, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.
5. A method for inhibiting PTEN, which comprises administering an effective amount of tetrazolylalkoxy-dihydrocarbostyril compound (I) or a salt thereof as set forth in claim 1 to a patient in need of such treatment.

6. The method according to claim 5, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

7. A use of tetrazolylalkoxy-dihydrocarbostyril compound (I) or a salt thereof as set forth in claim 1 in preparation of a medicament for inhibiting PTEN.

8. The use according to claim 7, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

9. A Maxi-K channel opener which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I):

![Chemical Structure](image)

wherein R is a cycloalkyl group, A is a lower alkylene group, and the bond between 3- and 4-positions of the carbostyril nucleus means a single bond or a double bond, or a salt thereof.
10. The Maxi-K channel opener according to claim 9, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

11. A pharmaceutical composition for opening of Maxi-K channel which comprises as an active ingredient the tetrazolyllalkoxy-dihydrocarbostyril compound of the formula (I) or a salt thereof as set forth in claim 9 in admixture with a conventional pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition according to claim 11, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

13. The pharmaceutical composition according to claim 11 or 12, which is for the treatment of a neuronal disorder.

14. The pharmaceutical composition according to claim 13, wherein the neuronal disorder is an Alzheimer's disease.

15. A method for opening of Maxi-K channel, which comprises administering an effective amount of tetrazolyllalkoxy-dihydrocarbostyril compound (I) or a salt thereof as set forth in claim 9 to a patient in need of such treatment.

16. The method according to claim 15, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-
yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

17. The method according to claim 15 or 16, which is for the treatment of a neuronal disorder.

18. The method according to claim 17, wherein the neuronal disorder is an Alzheimer's disease.

19. A use of tetrazolylalkoxy-dihydrocarbostyril compound (I) or a salt thereof as set forth in claim 9 in preparation of a medicament for opening of Maxi-K channel.

20. The use according to claim 19, wherein the active ingredient is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril or a salt thereof.

21. The use according to claim 19 or 20, which is for the preparation of a medicament for the treatment of a neuronal disorder.

22. The use according to claim 21, wherein the neuronal disorder is an Alzheimer's disease.
**Fig. 1**

![Graph showing the effect of TNF-α and cilostazol on P-PTEN/PTEN.](image)

### Legend:
- **P-PTEN/PTEN**
- **(None = 1)**
- **TNF-α (50 ng/ml)**
- **Cilostazol (μM)**

### Statistical Notations:
- **###** $P < 0.01$ vs. absence of TNF-α and cilostazol.
- ***P < 0.05; **P < 0.01** vs. TNF-α alone.
- **†P < 0.05** vs. cilostazol (10 μM) alone.
Fig. 3

Total A-Beta ELISA results
### A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/47 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, EMBASE, BIOSIS

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 4 277 479 A (NISHI TAKAO ET AL) 7 July 1981 (1981-07-07) column 1, line 48 - column 2, line 47 Co. 25, Example 26 Abstract</td>
<td>1-4,9-14</td>
</tr>
<tr>
<td>A</td>
<td>WO 94/14444 A (OTSUKA PHARMA CO LTD ; KUROKAWA ICHIROU (JP) ; KITAZAWA TOSHIKI (JP) ; K) 7 July 1994 (1994-07-07) Page 1, formula (1); abstract</td>
<td>1-22</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:
  * A: document defining the general state of the art which is not considered to be of particular relevance
  * E: earlier document but published on or after the international filing date
  * L: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  * O: document referring to an oral disclosure, use, exhibition or other means
  * P: document published prior to the international filing date but later than the priority date claimed

** T: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

** X: document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

** Y: document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

** S: document member of the same patent family

** Date of the actual completion of the International search **

** 23 June 2004 **

** Date of mailing of the international search report **

** 06/07/2004 **

** Name and mailing address of the ISA **

European Patent Office, P.B. 8818 Patentlaan 2 NL – 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Authorized officer

Rudolf, M
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>JP 56 049378 A (OTSUKA PHARMACEUT CO LTD) 2 May 1981 (1981-05-02) the whole document</td>
<td>1-22</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 55035019 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 61055514 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AR 229342 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 364363 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 584579 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 538410 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 5039779 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BE 878548 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 1139761 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 641799 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 2934747 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 363179 A, B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 483792 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 792699 A, B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2434809 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2033893 A, B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IT 1119929 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX 6749 E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NL 7906523 A, C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 792829 A, B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PH 18452 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 70136 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE 432252 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE 7907236 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SU 1064868 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 7904627 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9414444 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6239745 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9908716 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2319542 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1079764 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002537231 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9956666 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6541487 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 63020235 B</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.: 5, 6, 15-18

   because they relate to subject matter not required to be searched by this Authority, namely:

   Although claims 5, 6, 15-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

□ The additional search fees were accompanied by the applicant's protest.

□ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)